Liver function and impact on drug clearance

Overview

Hepatic impairment reduces drug clearance for hepatically-metabolised agents through reduced enzymatic metabolic capacity, reduced hepatic blood flow (affecting high-extraction drugs particularly), and reduced protein synthesis (increasing free fraction of highly protein-bound drugs) - unlike renal impairment, there is no single validated biomarker (equivalent to eGFR) providing a direct, standardised measure of hepatic drug-clearing capacity
Relevant to dosing consideration for any hepatically-metabolised drug in a patient with significant liver disease, a population where standard dosing references may not reliably apply

Liver function tests (transaminases, bilirubin, albumin, INR) reflect hepatocellular injury and synthetic function but do not directly measure metabolic clearance capacity for a specific drug - this explains why hepatic dose adjustment relies more on clinical severity assessment (e.g. Child-Pugh classification incorporating several of these parameters together) and drug-specific knowledge than on a single calculable formula as used for renal dosing

Child-Pugh classification (combining bilirubin, albumin, INR, ascites, and encephalopathy) provides a structured severity grading used to guide dose adjustment recommendations for many hepatically-cleared drugs, though this remains a less precise tool than renal function-based dosing formulas
Reduced hepatic first-pass metabolism in significant liver disease can substantially increase oral bioavailability of drugs normally subject to extensive first-pass clearance, sometimes requiring dose reduction disproportionate to what liver function tests alone would suggest

Dose reduction, extended dosing interval, or avoidance of hepatically-cleared drugs guided by severity (often via Child-Pugh classification) in significant hepatic impairment
Caution with drugs having a narrow therapeutic index and significant hepatic clearance dependence, given the imprecision of hepatic dose-adjustment compared with renal dose-adjustment tools

Child-Pugh classification and dose adjustment guidance, reduced first-pass metabolism increasing oral bioavailability in liver disease, hypoalbuminaemia and increased free drug fraction, absence of a hepatic equivalent to eGFR

Unlike renal impairment, there is no single validated biomarker providing a direct, standardised measure of hepatic drug-clearing capacity - hepatic dose adjustment relies on composite severity scores like Child-Pugh classification and drug-specific clinical knowledge, making it a less precise process than the eGFR-based dosing calculations available for renal impairment

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.